Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Alebund Reports Positive Phase II Data for Novel Therapy Aimed at Dialysis Side Effects

publication date: Dec 13, 2023

Shanghai Alebund Pharmaceuticals announced positive Phase II proof-of-concept results for its investigational drug, AP306, a first-in-class, pan-inhibitor of sodium-dependent phosphate transporters. Elevated phosphorus levels are a common problem for kidney patients on dialysis. At the end of AP306 treatment, the reduction of serum phosphorus from baseline was clinically significant; and the response rate (serum phosphorus lower than 5.5 mg/dL) for AP306 was much higher than for sevelamer carbonate, an existing therapy. Detailed results will be released in an upcoming scientific meeting. Alebund in-licensed global rights to the candidate from Chugai Pharma, including Japan. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here